The stage transition problem
A biologics company is not the same company at IND that it is at BLA. The cost structure changes. The capitalization rules change. The supply chain changes. The revenue model changes. ERP configurations that work for a clinical-stage company break the day commercial inventory exists.
Most ERP implementations assume a stable operating model. Biologics companies do not have one. The platform has to support 4 distinct operating modes: preclinical and IND-enabling work, clinical manufacturing across phases, BLA submission and pre-launch readiness, and commercial supply with biosimilar dynamics. As Archer's biotech and pharmaceuticals industry page describes, clinical-stage biotech companies carry one of the most complex finance profiles in existence: CRO accruals calculated outside the ERP, milestone revenue that lives in spreadsheets, and pre-IPO audit readiness built on goodwill. NetSuite, configured properly, handles all 4 stages without rebuild at each transition.
The IND to BLA transition is not a project. It is a configuration. If the ERP has to be rebuilt at every stage, it was not built for biologics in the first place.
Why generic ERP fails biologics operators
Four challenges recur.
R and D capitalization
Pre-approval, most spend is expensed. Post-approval, inventory capitalization rules shift dramatically. The ERP has to support both treatments, sometimes simultaneously, when manufacturing scale-up overlaps with regulatory approval.
CRO and CMO management
Clinical-stage biologics companies run on outsourced relationships. Purchase orders, accruals, milestone payments, and supplier performance tracking all live in the ERP, and they have to be configured for service-based contracts, not standard goods receipts.
21 CFR Part 11 compliance
Any ERP transaction that supports a GMP decision falls under FDA 21 CFR Part 11. Audit trail, electronic signature, and validation requirements apply to inventory, manufacturing, and quality data inside NetSuite. Per Oracle NetSuite documentation, the platform supports validation-ready audit trails and Part 11-compliant electronic records and signatures.
Biosimilar gross-to-net
For biosimilar launches, the gross-to-net curve is steeper and more compressed than originator products. ERP configurations have to support faster rebate accrual revision and more granular payer-level visibility.
How Archer configures NetSuite for biologics
Stage-based configuration. R and D capitalization rules are configured at the item and project level. Clinical lots flow to R and D expense. Validation lots flow to pre-launch inventory under defined criteria. Commercial lots flow to standard inventory with full COGS treatment. The transition is a configuration change, not a project.
CRO and CMO management runs as project-based procurement. Contract Lifecycle Management tracks milestone schedules and accruals. Vendor Onboarding and Approved Supplier List manage the supplier qualification process required under GMP.
21 CFR Part 11 configuration covers audit trail, electronic signature, and validation. Archer delivers the validation documentation as part of the implementation, not as a separate engagement. Approvals App and QMS map to the quality management system. Roles, permissions, and approval workflows are configured to support GMP decisions.
Biosimilar gross-to-net uses the specialty pharmacy waterfall approach extended for biosimilar-specific contract structures. Interchangeability designations, payer access dynamics, and reference product comparison flow into reporting that the commercial team can use.
Related on archerinsights.com
- Biotech and pharmaceuticals industry page. Archer's full configuration approach for clinical and commercial biotech.
- Cell and gene therapy industry page. Advanced therapy operating model.
- CRO industry page. Adjacent operating model for sponsor-side CRO management.
- Quality Management System. GMP and Part 11 compliant quality workflows.
- Material Requirements Planning for life sciences. Manufacturing planning configured for regulated production.
- Approvals App for SOX-ready workflows. Configurable approval routing with audit trail.
External references
- NetSuite Life Sciences ERP
- FDA 21 CFR Part 11: Electronic Records and Electronic Signatures
- ICH guidance: harmonized standards for biologics development
- ASC 606 Revenue Recognition Standard
Configure NetSuite for every stage you will operate in
A discovery call covers your current stage, the configuration that supports your next milestone, and what changes when commercial supply begins.